From Binding to Antibiotic Action: Phage Display as a Translational Platform for Antimicrobial Discovery, Antibiotic Rescue, and Precision Therapy
Authors:
- Abel Villa-ManceraAbel Villa-Mancera
- José Manuel Robles-RoblesJRJosé Manuel Robles-Robles
- Jaime Olivares-PérezJOJaime Olivares-Pérez
- Agustín Olmedo-JuárezAgustín Olmedo-Juárez
- Roberto González-GarduñoRGRoberto González-Garduño
- José Luis Ponce-CovarrubiasJPJosé Luis Ponce-Covarrubias
- Nallely Rivero-PerezNallely Rivero-Perez
- Felipe PatricioFelipe Patricio
- Huitziméngari Campos-GarcíaHCHuitziméngari Campos-García
- Maria José Robles-RosadoMRMaria José Robles-Rosado
- Juan Ricardo Cruz-AviñaJuan Ricardo Cruz-Aviña
- Samuel Ortega-VargasSOSamuel Ortega-Vargas
Open Access
- 26 October 2026
- journal article
- review article
- Published by MDPI AG in Applied Biosciences
- Vol. 5 (4) , 101
Abstract
Antimicrobial resistance threatens human and animal health, while the development of new antibacterial agents remains slow. Phage display can identify peptides and antibody fragments for bacterial targeting, antimicrobial engineering, antibiotic potentiation, delivery, and diagnostics. This narrative review examines the evidence needed to connect ligand selection with antibacterial benefit. We distinguish enrichment and phage-associated binding from the activity of the intended soluble or carrier-bound product, and compare functional, microbiological, safety, resistance, and translational endpoints. We propose the Binding-to-Antibiotic Action (B2A) framework as an unvalidated, application-specific guide to evidence requirements, organized around display-related limitations such as avidity, propagation bias, and non-native target presentation. Its five domains cover binding relevance, biological function, antibacterial or antibiotic-related benefit, safety and resistance, and translation. Diagnostic candidates require a parallel pathway based on analytical performance, clinical validity, and decision impact. Representative studies demonstrate enzyme inhibition, targeted antimicrobial peptides, antibiotic delivery, and bacterial detection; however, evidence remains heterogeneous and predominantly preclinical. Sequencing, computational design, and chemical diversification can support discovery but cannot replace experimental validation. The principal opportunity is to connect molecular recognition with measurable therapeutic or diagnostic benefit across human, veterinary, food, aquatic, and environmental settings.Keywords
This publication has 85 references indexed in Scilit:
- Phage‐displayed heptapeptide sequence conjugation significantly improves the specific targeting ability of antimicrobial peptides against Staphylococcus aureusmLife, 2024
- Aquaculture and Aeromonas hydrophila: a complex interplay of environmental factors and virulenceAquaculture International, 2024
- Exploring synergy and its role in antimicrobial peptide biology2022
- Biased selection of propagation-related TUPs from phage display peptide librariesAmino Acids, 2017
- Whole Cell Panning with Phage Display2017
- Phage display biopanning and isolation of target-unrelated peptides: in search of nonspecific binders hidden in a combinatorial libraryAmino Acids, 2016
- T4 bacteriophage as a phage display platformArchives of Microbiology, 2014
- Corruption of phage display libraries by target-unrelated clones: Diagnosis and countermeasuresAnalytical Biochemistry, 2010
- T7 lytic phage‐displayed peptide libraries exhibit less sequence bias than M13 filamentous phage‐displayed peptide librariesProteomics, 2006
- Antibody-selectable filamentous fd phage vectors: affinity purification of target genesGene, 1988